Advertisement
Collaboration › Details
Merck (DE)–Nucleai MD: AI-based biomarker discovery, 202106– long-term collab using ATOM platform for cancer biomarker discovery
Period | 2021-06-24 | |
Partner, 1st | Merck KGaA | |
Group | Merck (DE) (Group) | |
Partner, 2nd | Nucleai MD (IL) | |
Product | biomarker discovery technology | |
Product 2 | ATOM AI-powered image analysis platform | |
Nucleai MD. (6/24/21). "Press Release: Nucleai and Merck KGaA Darmstadt, Germany Launch Translational Medicine Collaboration Utilizing Nucleai’s AI-Powered Biomarker Platform". Chicago, IL.
Nucleai (www.nucleaimd.com), a precision medicine company using AI-powered image analysis technology to support novel pathology-based biomarker development, and Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that they have entered into a long-term collaboration to leverage Nucleai's image analysis and biomarker discovery platform for several Merck KGaA, Darmstadt, Germany clinical stage oncology assets.
As part of the collaboration, Merck KGaA, Darmstadt, Germany will leverage Nucleai’s platform for exploratory research, with the potential to further develop identified pathology-based biomarkers as companion diagnostics. The collaboration will further utilize Nucleai’s technology to expand onto Merck KGaA, Darmstadt, Germany’s analysis capabilities, enabling faster turnaround time and scale for future studies.
Nucleai's platform analyzes tissue images using computer vision and machine learning methods to model the tumor and the immune system's spatial characteristics, creating unique and specific histological biomarkers that may help predict patient response. These biomarkers hold the potential to provide better understanding of cancer biology, enable further stratification of responder/non-responder patient populations, and improve the success rate of clinical trials and patient care. To develop its platform, Nucleai leverages proprietary datasets of pathology images and clinical data from leading hospitals and Health Maintenance Organizations (HMOs) in the U.S and Israel.
“We are thrilled to announce another major collaboration with a leading pharmaceutical company like Merck KGaA, Darmstadt, Germany to identify and develop novel biomarkers for their oncology assets. By combining real world and clinical trial datasets, with an integrated and scalable technology platform, we are harnessing the power of AI and big data and setting the standard for future precision medicine collaborations, adds Avi Veidman, CEO and Co-Founder of Nucleai.”
About Nucleai
Nucleai is a precision medicine company that has developed an AI-powered image analysis platform to unlock the power of spatial biology from pathology images. Nucleai’s ATOM platform, built and trained off large-scale proprietary datasets, leverages computer vision and deep neural networks to structure and characterize tissue and cell architecture in pathology images to identify spatial characteristics that predict response to therapy and inform treatment decision. We are currently partnered with leading pharmaceutical companies to discover novel spatial biomarkers, develop pathology-based companion diagnostics assays and drive improved patient outcomes. For more information, please visit www.nucleaimd.com.
Contacts
Jonathan Daniels – VP of Sales
Jonathan@nucleaimd.com
Record changed: 2022-01-02 |
Advertisement
More documents for Merck (DE) (Group)
- [1] C4 Therapeutics, Inc.. (3/4/24). "Press Release: C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins". Watertown, MA....
- [2] Precirix N.V.. (2/29/24). "Press Release: Tom Plitz Commences Role as Chief Executive Officer of Precirix". Brussels....
- [3] Merck KGaA. (1/4/24). "Press Release: Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna [Not intended for UK-, US- or Canada-based media]". Darmstadt....
- [4] ITM Isotope Technologies Munich SE. (12/14/23). "Press Release: ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics". Garching....
- [5] Merck KGaA. (12/4/23). "Press Release: Merck Strengthens Oncology Portfolio through Commercialization Agreement With Abbisko for Phase III Asset, Pimicotinib [Not intended for UK-, US- or Canada-based media]". Darmstadt....
- [6] Merck KGaA. (11/21/23). "Press Release: Merck Expands Newest Biologics Testing Center in Shanghai". Shanghai....
- [7] Merck KGaA. (11/14/23). "Press Release: Merck Announces Plans for New U.S. Healthcare Headquarters in Boston’s Seaport District [Not intended for US-based media]". Darmstadt....
- [8] Merck KGaA. (10/30/23). "Press Release: Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate [Not intended for US-, Canada- or UK-based media]". Darmstadt...
- [9] Exscientia plc. (10/3/23). "Press Release: Exscientia Details Pipeline Prioritisation Strategy". Oxford....
- [10] BenevolentAI. (9/20/23). "Press Release: BenevolentAI Signs Strategic Collaboration with Merck". London....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top